Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
作者： Agnieszka Palucha , Andrzej Pilc
DOI: 10.1016/J.PHARMTHERA.2007.04.007
关键词:
摘要: Depression and anxiety represent a major problem. However, the current treatment of both groups diseases is not satisfactory. As glutamatergic system may play an important role in pathophysiology depression anxiety, we decided to discuss recent data on possible anxiolytic and/or antidepressant effects metabotropic glutamate (mGlu) receptor ligands. Preclinical indicated that antagonists group I mGlu receptors, particularly mGlu5 produced anxiolytic-like antidepressant-like effects. Clinical also demonstrated antagonist, fenobam, was active drug. The exerted by are profound, comparable with or stronger than those benzodiazepines. problem psychotomimetic activity their influence memory has be further investigated. Among all ligands, II agonists seem drugs most promising therapeutic potential good safety profile. Animal studies showed agonists. Currently, phase III clinical trials for disorders. On other hand, been accumulated, indicating receptors have potential. Group ligands least investigated receptors. preclinical indicates these antagonists,
elsevier.com
sci-hub.se 参考文章(360)
Agnes Baude, Zoltan Nusser, J.David B. Roberts, Eileen Mulvihill, R.A. Jeffrey Mcllhinney, Peter Somogyi, The metabotropic glutamate receptor (mGluRlα) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction Neuron. ,vol. 11, pp. 771- 787 ,(1993) , 10.1016/0896-6273(93)90086-7
Takao Yoshimizu, Toshiharu Shimazaki, Akie Ito, Shigeyuki Chaki, An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats Psychopharmacology. ,vol. 186, pp. 587- 593 ,(2006) , 10.1007/S00213-006-0390-7
A Pa³ucha, E Tatarczyñska, P Brañski, B Szewczyk, JM Wieroñska, A K³odziñska, E Chojnacka-Wójcik, Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology. ,vol. 46, pp. 151- 159 ,(2004) , 10.1016/J.NEUROPHARM.2003.09.006
Michael Davis, The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends in Pharmacological Sciences. ,vol. 13, pp. 35- 41 ,(1992) , 10.1016/0165-6147(92)90014-W
Christian Grillon, Jeremy Cordova, Louise R Levine, Charles A Morgan, III, Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans Psychopharmacology. ,vol. 168, pp. 446- 454 ,(2003) , 10.1007/S00213-003-1444-8
Hitoshi Ohishi, Ryuichi Shigemoto, Shigetada Nakanishi, Noboru Mizuno, Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: An in situ hybridization study The Journal of Comparative Neurology. ,vol. 335, pp. 252- 266 ,(1993) , 10.1002/CNE.903350209
Michael S. Cowen, Elvan Djouma, Andrew J. Lawrence, The Metabotropic Glutamate 5 Receptor Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine Reduces Ethanol Self-Administration in Multiple Strains of Alcohol-Preferring Rats and Regulates Olfactory Glutamatergic Systems Journal of Pharmacology and Experimental Therapeutics. ,vol. 315, pp. 590- 600 ,(2005) , 10.1124/JPET.105.090449
Michel Bourin, Myriam Malinge, Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam Progress in Neuro-psychopharmacology & Biological Psychiatry. ,vol. 19, pp. 567- 575 ,(1995) , 10.1016/0278-5846(95)00102-2
Ronald S Duman, George R Heninger, Eric J Nestler, A Molecular and Cellular Theory of Depression Archives of General Psychiatry. ,vol. 54, pp. 597- 606 ,(1997) , 10.1001/ARCHPSYC.1997.01830190015002
Jesse Brodkin, Chris Busse, Stacey J Sukoff, Mark A Varney, Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacology, Biochemistry and Behavior. ,vol. 73, pp. 359- 366 ,(2002) , 10.1016/S0091-3057(02)00828-6